## Observational Study in Multiple Sclerosis

Challenges in the DIFUTURE Use-Case


Heidi Seibold



Causal inference workshop, Zurich 12/2018

# **DIFUTURE**

**Data Integration for Future Medicine** 





#### Notation and Definitions

MS	Multiple sclerosis
cMRT	Cerebral magnetic resonance tomography (images of the brain)
sMRT	Spinal magnetic resonance tomography (images of the spine)
$t_i$	Month <i>i</i> after first relevant cMRT (= cMRT before treatment start)

# Develop a model which can be used for making individual treatment decisions in patients with MS

- Treatment success if no new or enlarged lesions visible in sMRT and cMRT between months 6 ( $t_6$ ) and 24 ( $t_{24}$ )
- 3 treatment options:
  - No treatment
  - Basic treatment
  - Strong treatment
- A variety of patient characteristics can potentially influence treatment success



Data collected as part of clinical routine at MRI (TU Munich).

<u>Outcome</u>

<u>Treatment</u>

**Baseline patient characteristics** 




#### Outcome:

New or enlarged lesions visible in sMRT and cMRT between  $t_6$  and  $t_{24}$  (yes/no)




- No sMRT
- cMRT "usually" around  $t_0$ ,  $t_{12}$  and  $t_{24}$  (not as needed  $t_0$ ,  $t_6$  and  $t_{24}$ ).










#### Treatment:

- If no treatment within the first 2 years after diagnosis: treatment = no treatment
- Otherwise: treatment = first treatment given
- Treatment switches are possible







#### Baseline patient characteristics:

- Many possible characteristics available
- Many missing values (potentially not missing at random)
- Data quality potentially low

# Challenges

### How to deal with the issue of censoring in the outcome?

- ullet We are interested in new or enlarged lesions between  $t_{
  m 6}$  and  $t_{
  m 24}$
- MRTs are mostly not done at these time points
- Can we use imputation methods?
- Can we use methods that can deal with censoring?

# How to deal with the fact that for most patients we have only one sMRT?

- Clinician say that we can assume that there is no spinal progression if no sMRT was conducted.
- Is there a way to account for the insecurity?

#### How to obtain causal treatment effects?

- Data is observational
- We want to be able to say why a patient should receive which treatment

#### What to do in case of treatment switches?

- Patients sometimes switch from one treatment to another during the study period
- Is there a way to account for this?
- Would it be ok to ignore treatment switches? If so, why?

# What to do with missing values in patient characteristics?

#### MS Use-Case DIFUTURE

#### What to do with other data issues?

- Treatment starts before first cMRT
- What to do if data quality in certain patient characteristics is bad?
- ..